MBX Biosciences, Inc.
MBX Biosciences, Inc. scores highest on Nitro (69) and lowest on Price (12). Its PosiPenta is 46.61 out of 100, around the middle of similar companies.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Details
PPrice
| P/E ratio | -20.46 |
| P/B ratio | 5.70 |
EEarnings
| Trailing EPS | ₹-224.63 |
| Forward EPS | ₹-376.83 |
NNitro
| Price | 4596.94 |
| 52-week high | 6884.98 |
| 52-week low | 1512.72 |
| Fall from 52-week high | 33.2% |
TTorque
| Return on equity (ROE) | -33.17% |
| Debt-to-equity | 0.01 |
AAnchor
| Beta (price swings) | 0.10 |
| Market cap | ₹22,138 Cr |
| Insider holding | 2.88% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is MBX Biosciences, Inc.'s PosiPenta score?
MBX Biosciences, Inc.'s PosiPenta is 46.61 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Which PosiPenta pillar is strongest for MBX Biosciences, Inc.?
Nitro (momentum), with a score of 69 out of 100: better than most similar companies.
Which PosiPenta pillar is weakest for MBX Biosciences, Inc.?
Price (valuation), with a score of 12 out of 100: much weaker than most similar companies.
Has MBX Biosciences, Inc.'s PosiPenta changed since last week?
Yes, it fell 1.00 points, from 47.61 to 46.61.
PositoAI is for research and education only and is not investment advice.